Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

MLA

Giles, Francis, et al. “Elacytarabine, a Novel 5′-Elaidic Acid Derivative of Cytarabine, and Idarubicin Combination Is Active in Refractory Acute Myeloid Leukemia.” Leukemia Research, vol. 36, no. 4, Apr. 2012, pp. e71–73. EBSCOhost, https://doi.org/10.1016/j.leukres.2011.12.010.

APA

Giles, F., Rizzieri, D., Ravandi, F., Swords, R., Jacobsen, T. F., & O, B. S. (2012). Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leukemia Research, 36(4), e71–e73. https://doi.org/10.1016/j.leukres.2011.12.010

Chicago

Giles, Francis, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen, and Brien, Susan O. 2012. “Elacytarabine, a Novel 5′-Elaidic Acid Derivative of Cytarabine, and Idarubicin Combination Is Active in Refractory Acute Myeloid Leukemia.” Leukemia Research 36 (4): e71–73. doi:10.1016/j.leukres.2011.12.010.